
Chief, Division of Breast Oncology @DanaFarber Tennis fan Mother of two teenage girls
Boston. MA
Joined December 2015
- Tweets8.8K
- Following641
- Followers13.1K
- Likes28.6K
Sara Tolaney retweeted
INTerpath-001 | Why do the RFS curves separate late?
Phase III | 1,137 patients | Resected stage IIB–IV melanoma
Intismeran (personalized mRNA vaccine) + pembrolizumab vs pembrolizumab alone.
🔹 Overall RFS: HR 0.58 (95% CI 0.45–0.75)
🔹 First 6 months: HR 0.99 — little apparent benefit.
🔹 After 6 months: HR 0.42 — greater relative benefit emerges.
🔹 24-month RFS: 82.2% vs 70.0% (+12.2 percentage points).
🔹 RMST at 24 months: 21.2 vs 19.9 months (+1.2 months).
Why the apparent contrast?
RMST captures the entire 24-month period, including the early overlap, whereas the later HR reflects stronger separation after 6 months.
Vaccine manufacturing and immune priming may contribute to delayed benefit.
Take-home: A delayed RFS benefit with encouraging separation; longer follow-up is needed to establish durability and OS impact.
📖 Long GV et al. NEJM, 2026.
DOI: 10.1056/NEJMoa2609762
#Melanoma #INTerpath001 #mRNAVaccine #Immunotherapy #Oncology
Sara Tolaney retweeted
Exercise as cancer therapy! Love to see the data and enthusiasm for exercise oncology therapy finally catching up to what many of us have known for many years!
med.stanford.edu/news/insigh…
#exerciseoncology @StanfordCancer
Sara Tolaney retweeted
🧬 MICROPLASTICS & CANCER — A LOOMING THREAT?
📖 The Lancet Oncology | 2026
🔹 Microplastics are ubiquitous — detected in blood, lungs, liver and placenta.
🔹 Lung: 70% of 100 bronchoscopy patients had detectable microplastics.
🔹 Prostate: 9/10 patients showed higher particle counts in tumour than benign tissue.
🔹 Colorectal & endometrial: Greater microplastic burden reported in malignant tissues.
🔹 Mechanisms: Inflammation, oxidative stress and endocrine disruption are biologically plausible.
⚠️ The critical question: Do microplastics contribute to cancer, or do malignant tissues preferentially accumulate them?
🎯 TAKE-HOME: Association is emerging. Causation remains unproven. No change in cancer screening or treatment is currently justified.
📚 Microplastics and cancer: a looming threat? Lancet Oncol. 2026;27:1193.
#Microplastics #CancerResearch #Oncology #LancetOncology #MVOnco
@larvol @OncoDaily @OncoAlert
Sara Tolaney retweeted
No better way to spend a Saturday😎
📍Princeton, N.J.
🕕Swimming Prelims 10 a.m. | Diving Prelims 12 p.m.
🕕Finals 6 p.m.
📺tinyurl.com/yk965ey5
📊tinyurl.com/ypjf69c7
📰tinyurl.com/bdcvm6zx
Sara Tolaney retweeted
We’re proud to be included on @Forbes' list of America's Best Employers for Healthcare Professionals. We’re committed to maintaining an environment where healthcare professionals feel supported, valued, and empowered to make an impact. bit.ly/4j9cCUd
Sara Tolaney retweeted
🎯 ADC resistance is more than target expression!
New @CellRepMed study uses spatial transcriptomics to identify determinants of T-DXd resistance:
• HER2 spatial heterogeneity
• Tumor–vessel distance
• Lysosomal processing
• Payload distribution
Important implications for NECTIN4-targeting ADCs in UC!
doi.org/10.1016/j.xcrm.2026.…
@OncoAlert @weoncologists @urotoday @Uromigos
@OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3
Sara Tolaney retweeted
SERENA-6 | A Positive Trial, But Is Universal Serial ctDNA Testing Justified?
🔹 3,209 screened → 548 ESR1-mutated → 315 randomised (9.8%).
🔹 Early camizestrant switching improved outcomes:
• PFS: HR 0.45
• PFS2: HR 0.63
🔹 First vs subsequent ESR1 detection:
• First test: PFS2 HR 0.48
• Later testing: PFS2 HR 0.84
Exploratory findings; no proven difference in treatment effect.
🔹 The bigger question: Does repeated ctDNA surveillance for everyone justify the testing burden, costs and clinical resources?
Take-home: Biomarker actionability is established in eligible patients. Universal surveillance utility remains an open question.
📖 Sun et al. Lancet Oncology. 2026;27:e533.
#SERENA6 #BreastCancer #ctDNA #ESR1 #PrecisionOncology #MedOnc
Sara Tolaney retweeted
Evidence on the mechanisms underlying ADC resistance continues to emerge.
A spatial transcriptomics study involving 13 patients with breast cancer treated with T-DXd suggests that not only HER2 expression levels but also its spatial distribution within the tumor may influence treatment response.
In HER2-low tumors, resistance was associated with pharmacokinetic barriers involving vascular accessibility, linker cleavage, and payload distribution. In HER2-positive tumors, EGFR/PI3K pathway activation appeared to play a more prominent role.
Despite the small sample size, these findings suggest that ADC resistance extends beyond target antigen loss. Tumor spatial architecture and intratumoral drug distribution may be equally important determinants of resistance.
cell.com/cell-reports-medici…
Sara Tolaney retweeted
Check out the #TroFuse032 study design for pembrolizumab plus sacituzumab tirumotecan or chemotherapy followed by pembrolizumab plus chemotherapy as neoadjuvant therapy for early-stage, #TripleNegativeBreastCancer or HR-low+/HER2- #BreastCancer.
🔓pubmed.ncbi.nlm.nih.gov/4287…
@JavierCortesMD @Prof_Nadia_H #AnnGarridoCastro #TNBC
Sara Tolaney retweeted
NRG-BR002 @JCO_ASCO
Adding metastasis-directed ablation (93% SBRT) to 1L systemic therapy did not improve PFS or OS in oligometastatic #BreastCancer (≤4 mets).
▪️ mPFS: 23 vs 19.5 months (HR 0.92; P = .42).
▪️ OS: HR 1.07; P = .52.
#BCSM @OncoAlert
ascopubs.org/doi/abs/10.1200…
Sara Tolaney retweeted
The warmest congratulations for @montypal and the whole @cityofhope on this richly deserved award!
@DanaFarber_GU @KidneyCancer
Sara Tolaney retweeted
Congratulations to our Center Director Dr. Panos Konstantinopoulos and Director of Research Dr. Alan D’Andrea on being named among the world’s most highly cited researchers in 2026! 👏
#CancerResearch #HighlyCited2026
We’re proud to announce that 35 of its researchers have been named to the Highly Cited Researchers list of 2026, released today by the Institute for Scientific Information at @Clarivate. View the list here: bit.ly/4AADMt1
Sara Tolaney retweeted
Check out the @harvardmed course on
#CancerSurvivorship
✅Learn to address long-term side effects
✅ Better support the medical and psychosocial survivor needs
✅ Use evidence-based tools and strategies to enhance care
Register for the course today! learn.hms.harvard.edu/progra…
Sara Tolaney retweeted
Congratulations @FilipaLynce This is a testament to your continued contribution to @DFCI_BreastOnc and your commitment to bringing the best care for patients through research, collaboration and excellent clinical practice @ASCO @SABCSSanAntonio @myESMO
💫Congratulations to @DanaFarber's Dr. Filipa Lynce (@FilipaLynce) who was recently promoted to Associate Professor of Medicine @harvardmed!
Sara Tolaney retweeted
💫Congratulations to @DanaFarber's Dr. Filipa Lynce (@FilipaLynce) who was recently promoted to Associate Professor of Medicine @harvardmed!
Sara Tolaney retweeted
Congratulations Jennifer. Very deserving and a great appointment to lead a department that has such a long term impact on patients. @DFCI_BreastOnc @SABCSSanAntonio @ASCO @myESMO
💫Congratulations to Dr. Jennifer Ligibel on being named Chief of the NEW Division of Comprehensive Survivorship and Hospital Medicine within the Department of Medical Oncology @DanaFarber!
Jennifer will lead clinical and research efforts bridging survivorship, integrative therapies, and a new program focused on metabolic health and its impact on cancer risk outcomes.
Sara Tolaney retweeted
このSTOP-HER2試験はすごく重要で結果が本当に楽しみ。
HER2陽性転移性乳がんで、長期奏効得られたあと、トラスツズマブもやめて良いのか。
結果次第だけど、再発後の根治と呼ばそうな集団を前向きに示せることになる。
良い結果が出ることを願う。
#SABCS26
The phase II STOP-HER2 trial followed patients with HER2-positive metastatic breast cancer who stopped trastuzumab after a sustained response. Heather Parsons, MD, MPH, presents December 11 at #SABCS26. bit.ly/4kNbpDi

ALT The image is a flyer for the San Antonio Breast Cancer Symposium featuring logos for UT Health San Antonio and AACR. The text reads: "Can patients with metastatic breast cancer stop HER2 treatment after years of disease control? STOP-HER2 | Phase II Trial. Heather A. Parsons, MD, MPH. December 11, 2026." At the bottom, it includes the website "sabcs.org" and "#SABCS26.
Sara Tolaney retweeted
⭐️#CancerSymposium speaker spotlight: Elizabeth A. Mittendorf, MD, PhD, MHCM, President @ASCO
Dr. Mittendorf is a breast surgical oncologist, physician-scientist, and national leader in multidisciplinary cancer care.
Join us TOMORROW, 11/20 ➡️ bit.ly/CCSymposium26
Sara Tolaney retweeted
In this Breast Cancer highlight discussion from #ESMO26 with @JavierCortesMD here is the data for the 4 studies we touched on!
✅ #NATALEE update
✅ #postMONARCH
✅ #TROPIONBreast02
✅ #InspireLM
#OncTwitter #bcsm #BreastCancer @myESMO
Closing off #ESMO26 highlights with #BreastCancer w/ @JavierCortesMD
✅ #NATALEE update
✅ #postMONARCH
✅ #TROPIONBreast02
✅ #InspireLM
Full 🗣️
⭐️ oncbrothers.com/esmo-breast-…
⭐️“Oncology Brothers” podcast
#OncTwitter #bcsm @OncUpdates @myESMO







































